Program

 

PROGRAM AT-A-GLANCE

MONDAY, OCTOBER 5, 2020

10:0010:10Howard Fillit, MD, Alzheimer’s Drug Discovery Foundation
10:1010:45KEYNOTE: Gene Therapy for Neurodegeneration
Ron Crystal, MD, Cornell University
10:4511:00POSTERS and COFFEE BREAK

Session I: NOVEL APPROACHES FOR NEUROINFLAMMATION

11:0011:05SESSION OVERVIEW
11:0511:20Preclinical Development of an Antibody Therapeutic and an Imaging Agent Targeting Fibrin-Mediated Neuroinflammation
Jeffrey Stavenhagen, PhD,TheriniBio
11:2011:35Phase 1b Study in AD Patients with Neuroinflammation
CJ Barnum, PhD, INmune Bio
11:3511:50Development of Novel Anti-Neuroinflammatory Small Molecule Drug Candidates
Linda Van Eldik, PhD, University of Kentucky
11:5012:05Imaging Brain Inflammatory States: Focus on CSF1R
Martin Pomper, MD, PhD, Johns Hopkins University
12:0512:15SESSION 1: PANEL DISCUSSION
12:1512:30POSTER SESSION and COFFEE BREAK
12:3013:30LUNCH and NETWORKING/POSTERS

Session II: METABOLIC AND MITOCHONDRIAL APPROACHES FOR ALZHEIMER’S DISEASE

13:3013:35SESSION OVERVIEW
13:3513:50A Mitochondrial Approach for Alzheimer’s Disease
TBA
13:5014:05Benfotiamine in Alzheimer’s Disease: A Pilot Study
Gary Gibson, PhD, Burke Neurological Institute
14:0514:20Effect of Novel GLP1 Analogue, Liraglutide on Microglial Activation and Cerebral Glucose Metabolism in Mild Alzheimer’s Disease
Paul Edison, MD, PhD, Imperial College London
14:2014:30SESSION II: PANEL DISCUSSION
14:3014:40POSTERS and COFFEE BREAK

Session III: EMERGING AREAS IN DRUG DEVELOPMENT FOR NEURODEGENERATION

14:4014:45SESSION OVERVIEW
14:4515:00The Role of Senescent Cells in Alzheimer’s Disease and Dementia
Darren Baker, PhD, MS, Mayo Clinic
15:0015:15Autophagy in Alzheimer’s Disease and Related Dementias
Ralph Nixon, MD, PhD, NYU Langone Health
15:1515:30APOE4 Leads to Breakdown in the Blood-brain Barrier Predicting Cognitive Decline
Berislav Zlokovic, MD, PhD, Keck School of Medicine, USC
15:3015:45Accelerating Therapy Development for Alzheimer’s: from Open Science to Open Drug Discovery
Suzana Petanceska, PhD, NIH/NIA
15:4515:55SESSION III: PANEL DISCUSSION
15:5516:30NETWORKING/POSTERS

TUESDAY, OCTOBER 6, 2020

10:0010:35KEYNOTE: Current State for Blood Biomarkers in AD
Henrik Zetterberg, MD, PhD, University of Gothenburg

Session IV: NEUROPROTECTION, SYNAPTIC HEALTH AND NEUROTRANSMITTERS

10:3510:40SESSION OVERVIEW
10:4010:55Novel Positive Allosteric Modulators of the Alpha1A-Adrenergic Receptor to Treat Alzheimer’s Disease
Dianne Perez, PhD, CCF
10:5511:10In Vivo Characterization of a GABA-A alpha-5 Positive Allosteric Modulator
Sharon Rosenzweig-Lipson, PhD, AgeneBio
11:1011:25Clinical Trial Results: Glutamate Modulator Riluzole in Patients with Mild Alzheimer’s Disease
Ana Pereira, MD, Icahn School of Medicine
11:2511:40SESSION IV: PANEL DISCUSSION
11:4012:30LUNCH and POSTERS
12:3013:30SESSION V: Start-up Forum

Session V: NOVEL BIOMARKERS IN ALZHEIMER’S DISEASE

13:3013:35SESSION OVERVIEW
13:3513:50Digital Biomarkers in Alzheimer’s Disease
Lampros Kourtis, PhD, Circadic
13:5014:05High Molecular Weight Kininogen (HKc) as a Diagnostic Tool for Alzheimer’s Disease
Sidney Strickland, PhD, The Rockefeller University
Erin Norris, PhD, The Rockefeller University
14:0514:20TABLOOD: A Biomarker Panel for Direct Assessment in Blood of Alzheimer’s Disease Patho-physiological Hallmarks
Douglas Galasko, MD, UCSD
14:2014:35Magnetic Susceptibility as a Biomarker for Alzheimer’s Disease
Chunlei Liu, PhD, UC Berkeley
14:3514:50Circulating Brain-Enriched MicroRNAs as Peripheral Biomarkers of Neurodegeneration
Kira Sheinerman, PhD, DiamiR
14:5015:05A Rapid Non-invasive Diagnostic Test to Predict Mild Cognitive Impairment and Early Alzheimer’s Disease
Hüseyin Firat, MD, PhD, Amoneta
15:0515:15SESSION V: PANEL DISCUSSION
15:1515:20CLOSING REMARKS
15:2016:00NETWORKING/POSTERS

CONFERENCE INTRODUCTION

Monday, October 5, 2020
10:00 US Eastern Time

Howard Fillit
Alzheimer’s Drug Discovery Foundation

 

Dr. Howard Fillit is ADDF’s Founding Executive Director and Chief Science Officer. His introduction will provide a welcome to our 21st International Conference on Alzheimer’s Drug Discovery, a brief update on ADDF’s recent progress and will highlight the framework for this year’s meeting.

KEYNOTES

Ronald Crystal
Weill Cornell Medical College

Henrik Zetterberg
University of Gothenburg

Gene Therapy for Neurodegeneration

Gene therapy is becoming an area of increasing interest for neurodegenerative diseases. Dr. Crystal is a pioneer in the field of gene therapy having carried out human trials in cystic fibrosis, cardiac ischemia, cancer and CNS disorders. This talk will highlight​ the challenges of gene therapy approaches for neurodegenerative diseases and potential solutions moving forward for Alzheimer’s disease.

Monday, October 5, 2020
10:10 US Eastern Time

Current State for Blood Biomarkers in AD

Current biomarkers for Alzheimer’s disease are often invasive, expensive and reliant on specialized equipment only available at large clinical research centers. A move towards blood biomarkers could lead to earlier diagnosis, more widely available tests, and streamlined clinical trials. Dr. Zetterberg is a leading expert and driver in this field. His talk will provide an overview of landscape and future directions for blood biomarkers in Alzheimer’s disease.

Tuesday, October 6, 2020
10:00 US Eastern Time

SESSIONS

SESSION I: Novel Approaches for Neuroinflammation

The field continues to learn more about the role that inflammation plays in the progression of Alzheimer’s pathology. This session highlights preclinical drug development, clinical trials and an imaging agent in development to target various aspects of neuroinflammation.

Lauren Friedman
ADDF

CHAIR
Session Overview

Jeffrey Stavenhagen
TheriniBio

Preclinical Development of an Antibody Therapeutic and an Imaging Agent Targeting Fibrin-Mediated Neuroinflammation

CJ Barnum
INmune Bio

Phase 1b Study in AD Patients with Neuroinflammation

Linda Van Eldik
University of Kentucky

Development of Novel Anti-Neuroinflammatory Small Molecule Drug Candidates

Martin Pomper
Johns Hopkins University

Imaging Brain Inflammatory States: Focus on CSF1R

 

Monday, October 5, 2020
11:00 US Eastern Time

 

Monday, October 5, 2020
11:05 US Eastern Time

 

Monday, October 5, 2020
11:20 US Eastern Time

 

Monday, October 5, 2020
11:35 US Eastern Time

 

Monday, October 5, 2020
11:50 US Eastern Time

PANEL DISCUSSION – SESSION I

Monday, October 5, 2020
12:05 – 12:15 US Eastern Time

POSTER SESSION/BREAK

This session will feature research from early investigators in the academic community focused on drug development for Alzheimer’s and related dementias.

Monday, October 5, 2020
12:15 – 12:30 US Eastern Time

LUNCH/NETWORKING/POSTERS

Monday, October 5, 2020
12:30 – 13:30 US Eastern Time

SESSION II: Metabolic and Mitochondrial Approaches for Alzheimer’s Disease

Mounting evidence suggests that energy dysregulation in the form of metabolic or mitochondrial changes can contribute to the progression of Alzheimer’s disease. This session features a company developing innovative new drugs targeting mitochondria and the presentation of two completed clinical trials in the space.

Meriel Owen
ADDF

CHAIR
Session Overview

TBA

A Mitochondrial Approach for Alzheimer’s Disease

Gary Gibson
Burke Neurological Inst.

Benfotiamine in Alzheimer’s Disease: A Pilot Study

Paul Edison
ICL

Effect of Novel GLP1 Analogue, Liraglutide on Microglial Activation and Cerebral Glucose Metabolism in Mild Alzheimer’s Disease

 

Monday, October 5, 2020
13:30 US Eastern Time

 

Monday, October 5, 2020
13:35 US Eastern Time

 

Monday, October 5, 2020
13:50 US Eastern Time

 

Monday, October 5, 2020
14:05 US Eastern Time

PANEL DISCUSSION – SESSION II

Monday, October 5, 2020
14:20 – 14:30 US Eastern Time

POSTER SESSION/BREAK

Monday, October 5, 2020
14:30 – 14:40 US Eastern Time

SESSION III: Emerging Areas in Drug Development for Neurodegeneration

The ADDF closely follows emerging areas of aging biology that could be targeted to halt, prevent and cure Alzheimer’s and related dementias. This session will feature overviews of some of these promising areas which include cellular senescence, autophagy and vascular contributions to dementia.

Nick McKeehan
ADDF

CHAIR
Session Overview

Darren Baker
Mayo Clinic

The Role of Senescent Cells in Alzheimer’s Disease and Dementia

Ralph Nixon
NS Kline Inst.

Autophagy in Alzheimer’s Disease and Related Dementias

Berislav Zlokovic
USC

APOE4 Leads to Breakdown in the Blood-brain Barrier Predicting Cognitive Decline

Suzana Petanceska
NIH/NIA

Accelerating Therapy Development for Alzheimer’s: from Open Science to Open Drug Discovery

 

Monday, October 5, 2020
14:40 US Eastern Time

 

Monday, October 5, 2020
14:45 US Eastern Time

 

Monday, October 5, 2020
15:00 US Eastern Time

 

Monday, October 5, 2020
15:15 US Eastern Time

 

Monday, October 5, 2020
15:30 US Eastern Time

PANEL DISCUSSION – SESSION III

Monday, October 5, 2020
15:45 – 15:55 US Eastern Time

POSTER SESSION/BREAK

Monday, October 5, 2020
15:55 – 16:30 US Eastern Time

SESSION IV: Neuroprotection, Synaptic Health and Neurotransmitters

Synaptic and neuronal degeneration have been linked to the cognitive decline experienced in Alzheimer’s and related dementias. This session underscores the innovative work in neuroprotection featuring new progress from companies and in academic labs as well as the results from two completed clinical trials.

Alessio Travaglia
ADDF

CHAIR
Session Overview

Dianne Perez
CCF

Novel Positive Allosteric Modulators of the Alpha1A-Adrenergic Receptor to Treat Alzheimer’s Disease

Sharon Rosenzweig-Lipson
AgeneBio

In Vivo Characterization of a GABA-A alpha-5 Positive Allosteric Modulator

Ana Pereira
ISMMS

Clinical Trial Results: Glutamate Modulator Riluzole in Patients with Mild Alzheimer’s Disease

 

Tuesday, October 6, 2020
10:35 US Eastern Time

 

Tuesday, October 6, 2020
10:40 US Eastern Time

 

Tuesday, October 6, 2020
10:55 US Eastern Time

 

Tuesday, October 6, 2020
11:10 US Eastern Time

 

Tuesday, October 6, 2020
11:25 US Eastern Time

PANEL DISCUSSION – SESSION IV

Tuesday, October 6, 2020
11:40 – 11:50 US Eastern Time

LUNCH and POSTERS

Tuesday, October 6, 2020
11:50 – 12:30 US Eastern Time

SESSION V: START-UP FORUM

This session will feature drug development programs being pursued by start-up companies.

Tuesday, October 6, 2020
12:30 – 13:30 US Eastern Time

SESSION VI: Novel Biomarkers in Alzheimer’s Disease

Biomarkers play an important role in many aspects of clinical care and development including diagnosis, prognosis, clinical trial enrollment, enrichment, monitoring and outcomes. This session will feature some of the most promising emerging fluid, digital and imaging biomarkers in development for Alzheimer’s disease.

Nicole Bjorklund
ADDF

CHAIR
Session Overview

Lampros Kourtis
Circadic

Digital Biomarkers in Alzheimer’s Disease

Sidney Strickland
The Rockefeller Univ.

High Molecular Weight Kininogen (HKc) as a Diagnostic Tool for Alzheimer’s Disease

Douglas Galasko
UC San Diego

TABLOOD: A Biomarker Panel for Direct Assessment in Blood of Alzheimer’s Disease Patho-physiological Hallmarks

Chunlei Liu
UC Berkeley

Magnetic Susceptibility as a Biomarker for Alzheimer’s Disease

 

Tuesday, October 6, 2020
13:30 US Eastern Time

 

Tuesday, October 6, 2020
13:35 US Eastern Time

 

Tuesday, October 6, 2020
13:50 US Eastern Time

 

Tuesday, October 6, 2020
14:05 US Eastern Time

 

Tuesday, October 6, 2020
14:20 US Eastern Time

Kira Sheinerman
DiamiR Biosciences

Circulating Brain-Enriched MicroRNAs as Peripheral Biomarkers of Neurodegeneration

Hüseyin Firat
Amoneta

A Rapid Non-invasive Diagnostic Test to Predict Mild Cognitive Impairment and Early Alzheimer’s Disease

 

Tuesday, October 6, 2020
14:35 US Eastern Time

 

Tuesday, October 6, 2020
14:50 US Eastern Time

PANEL DISCUSSION – SESSION VI

Tuesday, October 6, 2020
15:05 – 15:15 US Eastern Time

CONCLUSIONS

Tuesday, October 6, 2020
15:15 – 15:20 US Eastern Time

NETWORKING/POSTERS

Tuesday, October 6, 2020
15:20 – 16:00 US Eastern Time